Lys160
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys160  -  FAM134B (human)

Site Information
SWEVINSkPDERPRL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1881577500

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 )
Relevant cell line - cell type - tissue:
E.coli (bacterial) ( 1 ) , HEK293T (epithelial) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Treatments:
C646 ( 1 ) , EBSS ( 1 ) , nicotinamide ( 1 ) , siRNA ( 1 ) , thapsigargin ( 1 ) , trichostatin_A ( 1 )

Downstream Regulation
Effects of modification on FAM134B:
molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
autophagy, induced ( 1 )
Induce interaction with:
CAMK2A (human) ( 1 ) , FAM134B (human) ( 1 )

References 

1

Wang X, et al. (2023) A regulatory circuit comprising the CBP and SIRT7 regulates FAM134B-mediated ER-phagy. J Cell Biol 222
37043189   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.